REFERENCES
1. Mangano DT. Aspirin and Mortality from Coronary Bypass Surgery.N Engl J Med . 2002;347(17):1309-1317. doi:10.1056/NEJMoa020798
2. Musleh G. Does aspirin 6 h after coronary artery bypass grafting
optimise graft patency? Interact Cardiovasc Thorac Surg .
2003;2(4):413-415. doi:10.1016/S1569-9293(03)00181-6
3. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute
Coronary Syndromes without ST-Segment Elevation. N Engl J Med .
2001;345(7):494-502. doi:10.1056/NEJMoa010746
4. Verma S, Goodman SG, Mehta SR, et al. Should dual antiplatelet
therapy be used in patients following coronary artery bypass surgery? A
meta-analysis of randomized controlled trials. BMC Surg .
2015;15(1):112. doi:10.1186/s12893-015-0096-z
5. Deo SV, Dunlay SM, Shah IK, et al. Dual Anti-platelet Therapy After
Coronary Artery Bypass Grafting: Is There Any Benefit? A Systematic
Review and Meta-Analysis: DUAL ANTI-PLATELET THERAPY AFTER CORONARY
ARTERY. J Card Surg . 2013;28(2):109-116. doi:10.1111/jocs.12074
6. Mărginean A, Bănescu C, Scridon A, Dobreanu M. Anti-platelet Therapy
Resistance – Concept, Mechanisms and Platelet Function Tests in
Intensive Care Facilities. J Crit Care Med . 2016;2(1):6-15.
doi:10.1515/jccm-2015-0021
7. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA,
Diodati JG. A comparison of six major platelet function tests to
determine the prevalence of aspirin resistance in patients with stable
coronary artery disease. Eur Heart J . 2007;28(14):1702-1708.
doi:10.1093/eurheartj/ehm226
8. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement:
an updated guideline for reporting systematic reviews. BMJ .
Published online March 29, 2021:n71. doi:10.1136/bmj.n71
9. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the
assessment of the quality of nonrandomized studies in meta-analyses.Eur J Epidemiol . 2010;25(9):603-605.
doi:10.1007/s10654-010-9491-z
10. Furlan AD, Malmivaara A, Chou R, et al. 2015 Updated Method
Guideline for Systematic Reviews in the Cochrane Back and Neck Group:Spine . 2015;40(21):1660-1673. doi:10.1097/BRS.0000000000001061
11. Brambilla M, Parolari A, Camera M, et al. Effect of two doses of
aspirin on thromboxane biosynthesis and platelet function in patients
undergoing coronary surgery. Thromb Haemost .
2010;103(03):516-524. doi:10.1160/TH09-07-0470
12. Bednar F, Osmancik P, Hlavicka J, Jedlickova V, Paluch Z, Vanek T.
Aspirin is insufficient in inhibition of platelet aggregation and
thromboxane formation early after coronary artery bypass surgery.J Thromb Thrombolysis . 2009;27(4):394-399.
doi:10.1007/s11239-008-0225-y
13. Wang Z, Gao F, Men J, Ren J, Modi P, Wei M. Aspirin resistance in
off-pump coronary artery bypass grafting. Eur J Cardiothorac
Surg . Published online June 2011:S1010794011004714.
doi:10.1016/j.ejcts.2011.04.021
14. Nicola H, Ho KM. Aspirin Resistance Incidence and Associations
Between Aspirin Effect and Outcomes in Cardiac Surgery. Ann Thorac
Surg . 2019;108(6):1815-1821. doi:10.1016/j.athoracsur.2019.04.114
15. Petricevic M, Biocina B, Konosic S, Kopjar T, Kunac N, Gasparovic H.
Assessment of platelet function by whole blood impedance aggregometry in
coronary artery bypass grafting patients on acetylsalicylic acid
treatment may prompt a switch to dual antiplatelet therapy. Heart
Vessels . 2013;28(1):57-65. doi:10.1007/s00380-011-0216-3
16. Petricević M, Biocina B, Konosić S, et al. Definition of
acetylsalicylic acid resistance using whole blood impedance aggregometry
in patients undergoing coronary artery surgery. Coll Antropol .
2013;37(3):833-839.
17. Poston RS, Gu J, Brown JM, et al. Endothelial injury and acquired
aspirin resistance as promoters of regional thrombin formation and early
vein graft failure after coronary artery bypass grafting. J Thorac
Cardiovasc Surg . 2006;131(1):122-130. doi:10.1016/j.jtcvs.2005.08.058
18. Bednar F, Tencer T, Plasil P, et al. Evaluation of Aspirin’s Effect
on Platelet Function Early After Coronary Artery Bypass Grafting.J Cardiothorac Vasc Anesth . 2012;26(4):575-580.
doi:10.1053/j.jvca.2011.12.004
19. Gasparovic H, Petricevic M, Kopjar T, Djuric Z, Svetina L, Biocina
B. Impact of Dual Antiplatelet Therapy on Outcomes Among
Aspirin-Resistant Patients Following Coronary Artery Bypass Grafting.Am J Cardiol . 2014;113(10):1660-1667.
doi:10.1016/j.amjcard.2014.02.024
20. Bolliger D, Filipovic M, Matt P, et al. Reduced aspirin
responsiveness as assessed by impedance aggregometry is not associated
with adverse outcome after cardiac surgery in a small low-risk cohort.Platelets . 2016;27(3):254-261. doi:10.3109/09537104.2015.1083969
21. Wand S, Adam EH, Wetz AJ, et al. The Prevalence and Clinical
Relevance of ASA Nonresponse After Cardiac Surgery: A Prospective
Bicentric Study. Clin Appl Thromb . 2018;24(1):179-185.
doi:10.1177/1076029617693939
22. Yilmaz MB, Balbay Y, Caldir V, et al. Late saphenous vein graft
occlusion in patients with coronary bypass: possible role of aspirin
resistance. Thromb Res . 2005;115(1-2):25-29.
doi:10.1016/j.thromres.2004.07.004
23. Mannacio VA, Di Tommaso L, Antignan A, De Amicis V, Vosa C. Aspirin
plus clopidogrel for optimal platelet inhibition following off-pump
coronary artery bypass surgery: results from the CRYSSA (prevention of
Coronary arteRY bypaSS occlusion After off-pump procedures) randomised
study. Heart . 2012;98(23):1710-1715.
doi:10.1136/heartjnl-2012-302449
24. Youn YN, Yi G, Lee S, Joo HC, Yoo KJ. Posttreatment platelet
reactivity on clopidogrel is associated with the risk of adverse events
after off-pump coronary artery bypass. Am Heart J .
2014;167(6):818-825. doi:10.1016/j.ahj.2014.01.016
25. Zimmermann N, Kurt M, Wenk A, Winter J, Gams E, Hohlfeld T. Is
cardiopulmonary bypass a reason for aspirin resistance after coronary
artery bypass grafting? Eur J Cardiothorac Surg .
2005;27(4):606-610. doi:10.1016/j.ejcts.2004.12.010
26. Hiyasat B, Sabha D, Weshah S, Hani AB. Aspirin Resistance in
Patients Undergoing Coronary Artery Bypass Grafting. Jordan Med
J . 2014;48(1):11-20.
27. Kempfert J, Anger K, Rastan A, et al. Postoperative development of
aspirin resistance following coronary artery bypass. Eur J Clin
Invest . 2009;39(9):769-774. doi:10.1111/j.1365-2362.2009.02175.x
28. Gasparovic H, Petricevic M, Kopjar T, Djuric Z, Svetina L, Biocina
B. Dual antiplatelet therapy in patients with aspirin resistance
following coronary artery bypass grafting: study protocol for a
randomized controlled trial [NCT01159639]. Trials .
2012;13(1):148. doi:10.1186/1745-6215-13-148
29. Willemsen LM, Vlot EA, Janssen PWA, et al. Blood loss after coronary
artery bypass by aspirin responsiveness assessed with preoperative
VerifyNow aspirin testing. Res Pract Thromb Haemost . 2021;5(8).
doi:10.1002/rth2.12623
30. Tantry US, Bliden KP, Gurbel PA. Overestimation of Platelet Aspirin
Resistance Detection by Thrombelastograph Platelet Mapping and
Validation by Conventional Aggregometry Using Arachidonic Acid
Stimulation. J Am Coll Cardiol . 2005;46(9):1705-1709.
doi:10.1016/j.jacc.2005.05.090
31. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of Dose-Related
Effects of Aspirin on Platelet Function: Results From the
Aspirin-Induced Platelet Effect (ASPECT) Study. Circulation .
2007;115(25):3156-3164. doi:10.1161/CIRCULATIONAHA.106.675587
32. Frelinger AL, Li Y, Linden MD, et al. Association of
Cyclooxygenase-1-Dependent and -Independent Platelet Function Assays
With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting
for Cardiac Catheterization. Circulation . 2009;120(25):2586-2596.
doi:10.1161/CIRCULATIONAHA.109.900589
33. Crescente M, Castelnuovo AD, Iacoviello L, Vermylen J, Cerletti C,
Gaetano G de. Response variability to aspirin as assessed by the
platelet function analyzer (PFA)-100: A systematic review. Thromb
Haemost . 2008;99(01):14-26. doi:10.1160/TH07-08-0530
34. Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the
PFA-100TM closure time to predict cardiovascular
events in aspirin-treated cardiovascular patients: a systematic review
and meta-analysis. J Thromb Haemost . 2008;6(3):444-450.
doi:10.1111/j.1538-7836.2008.02897.x
35. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin
“resistance” and risk of cardiovascular morbidity: systematic review
and meta-analysis. BMJ . 2008;336(7637):195-198.
doi:10.1136/bmj.39430.529549.BE
36. Snoep JD. Association of Laboratory-Defined Aspirin Resistance With
a Higher Risk of Recurrent Cardiovascular Events: A Systematic Review
and Meta-analysis. Arch Intern Med . 2007;167(15):1593.
doi:10.1001/archinte.167.15.1593
37. Calderaro D, Pastana AF, Flores da Rocha TR, et al. Aspirin
responsiveness safely lowers perioperative cardiovascular risk. J
Vasc Surg . 2013;58(6):1593-1599. doi:10.1016/j.jvs.2013.06.061
38. Mayer K, Bernlochner I, Braun S, et al. Aspirin Treatment and
Outcomes After Percutaneous Coronary Intervention. J Am Coll
Cardiol . 2014;64(9):863-871. doi:10.1016/j.jacc.2014.05.049